MedTrace Logo

Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer

NCT02605044 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 123

Last updated 2019-02-11

No results posted yet for this study

Summary

The objective is to compare the efficacy and safety of masitinib in combination with FOLFIRI ( irinotecan, 5-fluorouracil and folinic acid) to placebo in combination with FOLFIRI in second line treatment of patients.

Conditions

Interventions

DRUG

Masitinib (AB1010)

DRUG

FOLFIRI

Sponsors & Collaborators

  • AB Science

    lead INDUSTRY

Principal Investigators

  • Julien Taieb, PhD, MD · Hôpital Européen Georges Pompidou, Paris, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-12-31
Completion
2017-12-31

Countries

  • France
  • Singapore
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02605044 on ClinicalTrials.gov